TY - JOUR
T1 - Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG)
T2 - Research objectives workshop 2003
AU - Okunieff, Paul
AU - Meyn, Raymond E.
AU - Teicher, Beverly A.
AU - Thomas, Charles R.
AU - Gaspar, Laurie E.
AU - Raben, David
AU - Giri, Shankar
AU - Lavey, Robert S.
AU - Turrisi, Andrew T.
AU - Swanson, Gregory P.
AU - Smalley, Stephen R.
PY - 2003/10
Y1 - 2003/10
N2 - To achieve the ultimate goal of cancer treatment, which is 100% cancer control with negligible toxicity, the therapeutic window must be enlarged, allowing for higher doses of beneficial treatments with reduced toxicity. The advent of image- and metabolism-guided therapy offers the best opportunity to date for combining modern radiation targeting and imaging techniques. Indeed, for the first time, it is reasonable to locally target metastatic disease with the goal of sterilization. Combining these focal radiation techniques with novel targeted antiproliferative agents and full-dose classic cytotoxic chemotherapy will become more effective as we learn to use these compounds in a less systemically toxic manner and as radiation fields become more defined. In addition, increasing numbers of biologic modifiers of normal tissue response are becoming available, and they suggest great promise for decreasing the normal tissue toxicity resulting from both radiation and chemotherapy treatments. Thus, radiation metastectomy for gross metastases, used together with systemic control of micrometastatic disease, may yield improved survival rates. This hypothesis is ready for testing in cancers of the breast, prostate, colon, and in sarcomas. Enlarging the therapeutic window is a major goal that would allow for an increasingly favorable therapeutic gain.
AB - To achieve the ultimate goal of cancer treatment, which is 100% cancer control with negligible toxicity, the therapeutic window must be enlarged, allowing for higher doses of beneficial treatments with reduced toxicity. The advent of image- and metabolism-guided therapy offers the best opportunity to date for combining modern radiation targeting and imaging techniques. Indeed, for the first time, it is reasonable to locally target metastatic disease with the goal of sterilization. Combining these focal radiation techniques with novel targeted antiproliferative agents and full-dose classic cytotoxic chemotherapy will become more effective as we learn to use these compounds in a less systemically toxic manner and as radiation fields become more defined. In addition, increasing numbers of biologic modifiers of normal tissue response are becoming available, and they suggest great promise for decreasing the normal tissue toxicity resulting from both radiation and chemotherapy treatments. Thus, radiation metastectomy for gross metastases, used together with systemic control of micrometastatic disease, may yield improved survival rates. This hypothesis is ready for testing in cancers of the breast, prostate, colon, and in sarcomas. Enlarging the therapeutic window is a major goal that would allow for an increasingly favorable therapeutic gain.
UR - http://www.scopus.com/inward/record.url?scp=10744229935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744229935&partnerID=8YFLogxK
U2 - 10.1097/01.coc.0000092253.71406.2b
DO - 10.1097/01.coc.0000092253.71406.2b
M3 - Article
C2 - 14528084
AN - SCOPUS:10744229935
SN - 0277-3732
VL - 26
SP - 522
EP - 529
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
IS - 5
ER -